1. Сметник В.П. Лечение и профилактика климактерических расстройств. Клин. фармакология. 1997; 6 (2): 86–91.
2. Panzer C, Guay A. Testosterone replacement therapy in naturally and surgically menopausal women. J Sex Med 2009; 6: 8–18.
3. Khatibi A, Agardh C.-D., Shakir Y A et al. Could androgen protect middle aged women from cardiovascular events. A population-based study of Swedish women. The Women's Healh in the Lund Area (WHILA) study. Climacteric 2007; 10 (5): 386–92.
4. Manolakou P, Angelopoulou R, Bakoyiannis C, Bastounis E. The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression. Reprod Biol Endocr 2009; 7: 44.
5. Tok EC, Ertunc D, Oz U et al. The effect of circulating androgens on bone mineral dencity in postmenopausal women. Maturitas 2004; 48 (3): 235–42.
6. Maia H, Casoy J, Valente J. Testosterone replacement therapy in climacteric: benefits beyond sexuality. Gynecol Endocrin 2009; 25 (1): 12–20.
7. Калинченко С.Ю., Апетов С.С. Применение андрогенов у женщин в климактерическом периоде. Лечащий врач. 2009; 3: 28–30.
8. Калинченко С.Ю., Апетов С.С. Роль андрогенов у женщин – что мы знаем? Лечащий врач. 2010; 8: 82–6.
9. Радзинский В.Е., Калинченко С.Ю., Апетов С.С. Терапия андрогенами в гинекологической практике. Вестн. РУДН. 2010; 6: 196–204.
10. Калинченко С.Ю., Апетов С.С., Греков Е.А., Тишова Ю.А. Влияние женской андрогенной недостаточности и ее коррекции на нарушение мочеиспускания у женщин в постменопаузе. Лечащий врач. 2012; 3: 20–3.
11. Bachmann GA, Bancroft J, Braunstein G et al. Female androgen insufficiency: the Princeton consensus statement on definition, classification and assessment. Fertil Steril 2002; 77: 660–5.
12. Salpeter SR, Walsh JME, Ormiston TM et al. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diab Obes Metab 2006; 8: 538–54.
13. Rosano G, Vitale C, Silvestri A, Fini M. Metabolic and vascular effects of progestins in post-menopausal women. Implications for cardioprotection. Maturitas 2003; 46S: S17–29.
14. Miller KK, Biller BM, Shaub A et al. Effects of testosterone therapy on cardiovascular risk markers in androgen-deficient women with hypopituitarism. J Clin End Met 2007; 92 (7): 2474–9.
15. Simoncini T, Mannella P, Fornari L et al. Differential signal transduction of progesterone and medroxyprogesterone acetate in human endothelial cells. Endocrinology 2004; 145: 5745–56.
16. Ho JY-P, Chen M-J, Sheu WH-H et al. Differential effects of oral conjugated equine estrogen and transdermal estrogen on atherosclerotic vascular disease risk markers and endothelial function in healthy postmenopausal women. Hum Reprod 2006; 21: 2715–20.
17. Xing D, Miller A, Novak L et al. Estradiol and progestins differentiallymodulate leukocyte infiltration after vascular injury. Circulation 2004; 109: 234–41.
18. Otsuki M, Saito H, Xu X et al. Progesterone, but not medroxyprogesterone, inhibits vascular cell adhesion molecule-1 expression in human vascular endothelial cells. Arterioscler Thromb Vasc Biol 2001; 21: 243–8.
19. Simoncini T, Mannella P, Fornari L et al. In vitro effects of progesterone and progestins on vascular cells. Steroids 2003; 68: 831–6.
20. Sorensen KE, Dorup I, Hermann AP, Mosekilde L. Combined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97: 1234–8.
21. Rosano GMC, Webb CM, Chierchia S et al. Natural progesterone, but not medroxyprogesterone acetate, enhances the beneficial effect of estrogen on exercise-induced myocardial ischemia in postmenopausal women. J Am Coll Cardiol 2000; 36: 2154–9.
22. Gerhard M, Walsh BW, Tawakol A et al. Estradiol therapy combined with progesterone and endothelium-dependent vasodilation in postmenopausal women. Circulation 1998; 98: 1158–63.
23. Wakatsuki A, Okatani Y, Ikenoue N, Fukaya T. Effect of medroxyprogesterone acetate on endothelium-dependent vasodilation in postmenopausal women receiving estrogen. Circulation 2001; 104: 1773–8.
24. Simoncini T, Caruso A, Giretti MS et al. Effects of dydrogesterone and of its stablemetabolite, 20-alpha-dihydrodydrogesterone, on nitric oxide synthesis in human endothelial cells. Fertil Steril 2006; 86: 1235–42.
25. Worboys S, Kostopoulos D, Teede H et al. Evidence that parenteral testosterone therapy may improve endothelium-dependend and endothelium-independend vasodilatation in postmenopausal women already receiving estrogen. J Clin Endocr Met 2001; 86 (1): 158–161.
26. Кузнецова И.В. Метаболические эффекты дидрогестерона в составе препаратов для заместительной гормональной терапии. Cons. Med. 2012; 6.
27. Adolf E. Schindler. Progestational effects of dydrogesterone in vitro, in vivo and on the human endometrium, Maturitas 2009;65 Suppl (1):S3-11.

C.Ю.Калинченко, С.С.Апетов 

Кафедра эндокринологии ФПКМР ГБОУ ВПО РУДН, Москва